MANGOCEUTICALS, INC. Files 8-K on Security Holder Vote Matters

Ticker: MGRX · Form: 8-K · Filed: Jun 18, 2024 · CIK: 1938046

Mangoceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyMangoceuticals, INC. (MGRX)
Form Type8-K
Filed DateJun 18, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

TL;DR

MANGOCEUTICALS, INC. is submitting key decisions to shareholders for a vote.

AI Summary

On June 17, 2024, MANGOCEUTICALS, INC. filed an 8-K report to announce the submission of matters to a vote of its security holders. The company, incorporated in Texas with its principal executive offices in Dallas, is subject to the 1934 Securities Exchange Act.

Why It Matters

This filing indicates that MANGOCEUTICALS, INC. is engaging in a process that requires shareholder approval, which could lead to significant corporate actions or changes.

Risk Assessment

Risk Level: low — The filing is a procedural notification about a shareholder vote, not an announcement of a specific event with immediate financial implications.

Key Players & Entities

FAQ

What specific matters are being submitted to a vote of MANGOCEUTICALS, INC. security holders?

The filing does not specify the exact matters to be voted on, only that matters are being submitted for a vote.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on June 17, 2024.

In which state is MANGOCEUTICALS, INC. incorporated?

MANGOCEUTICALS, INC. is incorporated in Texas.

What is the principal executive office address for MANGOCEUTICALS, INC.?

The principal executive office is located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248.

Under which section of the Securities Exchange Act is this Form 8-K filed?

This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Stats: 844 words · 3 min read · ~3 pages · Grade level 11.8 · Accepted 2024-06-17 18:45:31

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: June 17, 2024 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing